{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380588388340103427.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Christine K. Ward"}],"foaf:familyName":[{"@value":"Ward"}],"foaf:givenName":[{"@value":"Christine K."}]}],"career":[{"institution":{"notation":[{"@value":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360588388340103424","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1182/blood-2021-152225"},{"@type":"URI","@value":"https://ashpublications.org/blood/article/138/Supplement%201/2488/478839/TAK-981-a-First-in-Class-SUMO-Activating-Enzyme"}],"notation":[{"@value":"TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood-2021-152225_2csMB8ZCviporTInAthQA9zSgCi"}]}